Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Revenue (2023 - 2025)

Historic Revenue for Immunome (IMNM) over the last 3 years, with Q2 2025 value amounting to $4.0 million.

  • Immunome's Revenue rose 6983.93% to $4.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year decrease of 444.27%. This contributed to the annual value of $9.0 million for FY2024, which is 3550.44% down from last year.
  • Immunome's Revenue amounted to $4.0 million in Q2 2025, which was up 6983.93% from $2.9 million recorded in Q1 2025.
  • Immunome's Revenue's 5-year high stood at $4.3 million during Q2 2023, with a 5-year trough of $1.0 million in Q1 2024.
  • Over the past 3 years, Immunome's median Revenue value was $2.9 million (recorded in 2024), while the average stood at $3.0 million.
  • In the last 5 years, Immunome's Revenue plummeted by 5647.21% in 2024 and then soared by 18435.37% in 2025.
  • Immunome's Revenue (Quarter) stood at $3.8 million in 2023, then decreased by 28.44% to $2.7 million in 2024, then surged by 46.64% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q2 2025, $2.9 million for Q1 2025, and $2.7 million during Q4 2024.